Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Recurrence × Dexamethasone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Recurrence 1 Neoplasms 1 Lymphoproliferative Disorders 1 Immunoproliferative Disorders 1 Carcinoma, Non-Small-Cell Lung 1 Burkitt Lymphoma 1

Interventions

tisagenlecleucel 2 blinatumomab 2 zanubrutinib 1 selinexor 1 revumenib 1 niraparib 1 nilotinib 1 ivosidenib 1 imetelstat 1 idecabtagene vicleucel 1 ibrutinib 1 fludarabine 1 entrectinib 1 dostarlimab 1 avapritinib 1 asciminib 1 Standard of Care 1 Paclitaxel 1 Imatinib Mesylate 1 GRN163L peptide 1 Drug Therapy 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Carboplatin 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03110562 2024-08-21

BOSTON

Karyopharm Therapeutics Inc

Phase 3 Completed

402 enrolled 22 charts 2 FDA

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡